Fig 1: Immunostaining, western blotting and reverse transcription-quantitative PCR analysis of target protein and mRNA expression levels after transfection. (A) Protein expression levels of cTnI in BMSCs were assessed using immunostaining with cTnI-specific primary antibodies and a Cy3 secondary antibody. Scale bar, 50 µm. (B) Quantitative analysis of the relative mRNA expression levels of HCN4, a-SA and cTnI. (C) Western blotting demonstrated increased HCN4, a-SA and cTnI protein expression levels. BMSCs without transfection were used as the control and BMSCs transfected with the empty vector were used as the NC. **P<0.01. cTnI, cardiac troponin I; HCN4, hyperpolarization-activated cyclic nucleotide-gated channel 4; a-SA, a-striated actin; NC, negative control; CM, cardiomyocyte; BMSCs, bone marrow mesenchymal stem cells.
Fig 2: Expression of target protein after G9a inhibition treatment. (A) Western blotting demonstrated increased HCN4, a-SA and cTnI protein expression levels in different groups. (B) Quantitative analysis of the mRNA expression levels of HCN4, a-SA and cTnI. (C) Chromatin immunoprecipitation-qPCR analysis for H3K9me2 binding to the HCN4 promoter. The histogram showed the amount of immunoprecipitated DNA as detected using the qPCR assay. Values are indicated as % of input. *P<0.05 and **P<0.01. cTnI, cardiac troponin I; HCN4, hyperpolarization-activated cyclic nucleotide-gated channel 4; a-SA, a-striated actin; CM, cardiomyocyte; BIX, H3K9me2, histone H3 at lysine 9 dimethylation; Tbx18, T-box 18 overexpression plasmid.
Supplier Page from Proteintech Group Inc for HCN4 antibody